You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration. Dr. Okun is also the author of the Amazon #1 Parkinson's Best Seller 10 Secrets to a Happier Life.
I know that for most of my patients with Parkinson’s disease, one of the keys to success is a fully engaged caregiver. Caregivers play an important role in helping their loved ones cope with the impact of the disease and the complexity of home-care regimens. Caregiving is not easy and it can be more than a full time job. It is always hard for a spouse-caregiver to watch increasing disability in their once-vibrant partner. Helen Keller’s caregiver, Anne Sullivan, once said, "I cannot explain it, but when difficulties arise, I am not perplexed or doubtful. I know how to meet them." A new study from the National Parkinson Foundation is highlighting just how important the caregiver is.
In our Parkinson’s Outcome Project, we have assembled the largest longitudinal cohort of Parkinson’s disease patients ever assembled in a clinical study. We have been collecting a measure called the multi-dimensional caregiver strain index on all of the spouses and caregivers in the study, and we have learned that recognizing and treating caregiver strain is critical.
We took the data we collected and asked, how can we show the importance of the caregiver to a person with Parkinson’s and how can we show the dramatic impact of being a caregiver on the people thrust into this role? To understand this, we decided to look at situations where the caregiver changed. How hard was it to be thrust into the role of being a caregiver in the middle of the course of a patient’s disease?
We expected to find that caregiver strain was higher for new caregivers, and we did. When a patient changed from having his or her spouse as caregiver to having another family member, the caregiver strain increase was 20 points higher that it was a year earlier when the spouse was the caregiver. For patients where the spouse stayed the caregiver, the change was just 5 points. In this 72 point scale, this 15 point difference is 20% of the way from no impact at all to intolerable strain, and is quite serious.
However, we noticed some other factors: Patients who switched from having their spouse as their caregiver to another family member also suffered worse health. They got sicker (they were more likely to move up the Hoehn and Yahr scale), they reported worse health on a health status questionnaire (the PDQ-39), and they suffered slower mobility that we measured in our clinics.
We realized that not only do experienced caregivers have well developed coping skills, but they also provide better care and better health to their loved ones.
In another study, Tanya Simuni at the NPF Center of Excellence at Northwestern University examined the impact that caregiver strain had on patients, also using data from our large Parkinson’s Outcome Project. She found that the better the patient reported their own health, the lower the caregiver strain. This was important because we also measured the patient’s disease clinically, and it was more patients’ perception of their health that determined strain than the clinical measurement of the impact of the disease.
This new evidence of the impact of caregivers has really shed new light on how I look on the concerned spouse who accompanies my patients to their visits with me. Caregivers are an integral part of care, and we found that a happy, knowledgeable caregiver not only is better able to cope with the stress of caregiving; he or she also is just as important as any other member of the care team. While I tell my patients what pills to take and encourage them to exercise, when the going gets tough it’s the caregivers who keep them fighting on, and it’s the caregivers who give them the encouragement and embody a reason to work to achieve the best lives they can. I’ve known this in my heart since I started treating people with Parkinson’s, but this important research will help us to prove that it’s true, and also to set a baseline to measure the things we do to make life better for people with Parkinson’s and their loved ones in the future.
Posted: 9/6/2013 1:14:03 PM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
Is light therapy a potential treatment modality in Parkinson’s disease?
How does the most common genetic cause of Parkinson’s Disease (LRRK2) cause Parkinson’s disease and could it be used to help develop a better therapy?
An Update on DAT Scanning for Parkinson’s Disease Diagnosis
Could Northera (Droxidopa) Be an Alternative Treatment for Low Blood Pressure and Passing Out Symptoms?
The Dream of a Pill Free Existence and the Continuous Dopaminergic Pump for the Treatment of Parkinson's Disease
Should I take Inosine to Raise my Uric Acid Levels and Treat my Parkinson’s Disease?
Could Fungus and Mold be an Important Contributor to Parkinson’s Disease?
Pimavanserin and the Hope for a Better Drug for Hallucinations and Psychosis in Parkinson’s Disease
Halting of the Creatine Study
The Importance of Identifying and Treating Caregiver Strain
Putting Parkinson’s Disease Information into the Palm of Your Hand: Parkinson’s Enters the Smartphon
What Parkinson’s Disease Patients Need to Know about H. Pylori Gastrointestinal Infections
A2A Receptor Antagonists and Parkinson’s Disease Treatment
Another Setback for Trophic Factor Treatment in Parkinson's Disease
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease